Apeiron Partners LLC announces exclusive licensing agreement between Solstice Neurosciences, Inc. and DreamPharma Corp. for cosmetic and therapeutic uses of Myobloc^®/Neurobloc^® in Korea

Framingham, MA, July 26, 2006

Solstice Neurosciences, Inc. announced that it has reached an Exclusive License Agreement with DreamPharma Corporation of Seoul, Korea, to evaluate and develop cosmetic and therapeutic uses of Myobloc® (Botulinum Toxin Type B) Injectable Solution for a range of specialty biopharmaceutical products in Korean markets. Apeiron Partners LLC, a boutique life-science investment bank based in Boston, advised Solstice on the transaction. The terms of the transaction have not been disclosed. The agreement includes the use of Myobloc® in its injectable formulation which was approved by the FDA in December 2000 and subsequently approved by the European Medicines Agency (EMEA) in January 2001.

This product, also known as Neurobloc® in Europe, is approved in 26 EU countries and distributed in Austria, France, Germany, Ireland, Italy, Portugal, Spain, United Kingdom, and the United States.

DreamPharma Corporation, a subsidiary of the HANWHA Group in Seoul, Korea, is involved in priority research and development for aesthetic/cosmetic, metabolic (obesity) (Phase III clinical trials), urinary/dermatological (Phase II clinical trials), respiratory, and oncology products to supplement its existing product portfolio in these and other areas. The company has numerous business partners and network affiliations worldwide. For more information about DreamPharma, visit www.dreampharma.co.kr.

“This agreement leverages Apeiron’s experience and contacts in Asia to maximize the value of the Myobloc® franchise, to our client Solstice Neurosciences, in Korea,” said Jeffrey D. Wager, MD, a Managing Director at Apeiron Partners.

About Apeiron Partners LLC
Apeiron Partners LLC, headquartered in Framingham, Massachusetts, is a boutique investment bank focused exclusively on the life sciences. Apeiron works closely with clients to create and implement strategies that maximize corporate value through the creative structuring of strategic alliances and financings.

Founded in 1995, Apeiron Partners (which changed its name from CPP Advisors in 2005) has a strong track record of success in the life science sector. Since its founding, Apeiron Partners has worked on over 40 assignments, designing and negotiating a wide variety of transactions in the process.

With an extensive relationship network in all three major life science markets of North America, Europe and Japan, Apeiron enables its clients to pursue partnering, M & A and investment opportunities worldwide.